TIDES USA 2022: Meet us in Boston

During TIDES USA 2022, connect with our experts to resolve your challenges for oligonucleotide, mRNA and peptide analytical and drug delivery challenges in Boston, USA. Meet our team at Booth 319.

Join our team at TIDES USA 2022 to discuss your challenges in oligonucleotide, mRNA or peptide development. Learn from our experts leading strategies for expediting R&D and improving CMC efficiency. Meet our team at Booth 319.

Hybrid Event (in-person and online) 
Where: Live In-Person Conference in Boston, USA 
When: May 9-12, 2022

To arrange a meeting, please email us: oligos@intertek.com

Oligonucleotide CMC Analytical Developments
Learn more about CMC analytical strategies for both drug substance and drug product to accelerate oligonucleotide product development. Learn More:


Peptide Analytical and Formulation Development
Overcome challenges in product development and quality control through tailored QC analytical strategies - learn more:


mRNA Therapeutics/Vaccines Analytical Development
Learn more about CMC analytical approaches for mRNA therapeutics and vaccines from experts, and learn about advanced analytical approaches:

Inhaled and Intranasal Drug Delivery Innovation
The delivery of oligonucleotides, peptides, mRNA therapeutics the targeted delivery approaches including orally inhaled and intranasal delivery. Learn more: 

  

 

Learn more and register for: TIDES USA 2022

 

Intertek's capabilities supporting CMC, manufacturing and commercialization of oligos, peptides or mRNA therapeutics and vaccines

    For nearly 30 years we have helped the world’s most innovative pharmaceutical and biopharmaceutical companies to navigate the challenges of new product development, drug delivery, production and market release. We provide a broad range of cGMP, GLP, GCP laboratory services, with a focus on support for the development and production of mRNA, oligos, peptides, biologics or vaccines. We are adept in establishing GMP validated analytical methods including mRNA specific methods such as integrity, potency, capping efficiency, residual DNA template, residual dsRNA and delivery system testing (e.g. lipid nanoparticles (LNPs)). These comprehensive characterisation services provide data to determine protein expression and product purity, which can be directly linked to translation efficiency and immunogenicity. We also provide ICH stability and formulation development programs and have leading expertise for inhaled and nasal drug product development.

    Oligonucleotide analysis | Oligonucleotide characterisation
    mRNA characterisation and analysis | Peptide analysis and formulation
    Development and validation | Physico-chemical characterisation
    Cell based potency assays | Purity determination and impurity analysis
    Aggregation analysis | Bioanalysis

    Need help or have a question? +44 161 721 5247
     
     
     

    Need help or have a question?

    +44 161 721 5247
    EMEA UK:
    +44 161 721 5247